Drug Deal Disclosure Act

Public release of drug deals

This bill would require HHS to post online, in a searchable downloadable format, records about covered drug pricing agreements. It would cover agreements entered on or after January 20, 2025 and require existing covered agreements to be posted within 30 days after enactment. The bill lists many manufacturer deals that meet the rules (for example, Pfizer on September 30, 2025; Novo Nordisk on November 6, 2025; AbbVie on January 12, 2026). HHS could only redact narrow proprietary pricing or pricing barred from disclosure by foreign law, and would have to publish written justifications for any redactions and say whether confidential pricing was provided by each manufacturer. The Secretary must give Congress a report within 15 days after the release listing documents released and withheld. Within 90 days after the release, CBO and the Comptroller General would jointly report on the agreements' economic and budget effects, including impacts on Medicare, Medicaid, ACA exchange plans, uninsured out-of-pocket costs, competition, and related program design issues.